← SynDRA
ABIRATERONE
SynDRA canonical compound SYN0008528 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | CYP17A1 |
|---|
| Mechanism of action | Androgen biosynthesis inhibitor |
|---|
| Indication | prostate cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- CYP17A1
- CYP11B1
- CYP2C19
- CYP2C8
- CYP3A5
- CYP3A4
- AR
- CYP11B2
- Cyp17a1
Mechanisms of action (all sources)
- Androgen biosynthesis inhibitor
- CYP17A1 INHIBITOR
- CYP17A1 MODULATOR
- Cytochrome P450 17A1 inhibitor
Drug classes
- Antineoplastic Agents
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Hormone Antagonists
- Metabolic Side Effects of Drugs and Substances
- Steroid Synthesis Inhibitors
- Cytochrome P450 2D6 Inhibitors
- Cytochrome P450 17A1 Inhibitors
- Cytochrome P450 17A1 Inhibitor
- Cytochrome P450 2C8 Inhibitors
ATC classes
- HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- Zytiga
- Abiraterona
- CB-7598
- NSC-741232
- Abiraterone (AR inhibitor)
- NSC 741232
- abiraterone (usp impurity)
- G819A456D0
- CB7598
- CHEBI:68642
- abirateronum
- RefChem:57133
- L02BX03
- DTXCID501021626
- Abiraterone (CB-7598)
- MFCD00924100
- Abiraterone [INN:BAN]
- Abirateron;
- UNII-G819A456D0
- Abiraterone (Standard)
- ABIRATERONE [MI]
- ABIRATERONE [INN]
- ABIRATERONE [VANDF]
- CB 7630 [as acetate]
- SCHEMBL61108
- ABIRATERONE [WHO-DD]
- MLS006010235
- US9487554, Abiraterone
- GTPL6745
- orb1300971
- orb3141293
- Abiraterone - Bio-X trade mark
- SCHEMBL29359971
- BDBM25458
- EX-A106
- GZOSMCIZMLWJML-VJLLXTKPSA-N
- ABIRATERONE [USP IMPURITY]
Reported adverse events
- Cardiac failure
- Fracture
- Hypertension
- Hepatotoxicity
- Cardiac disorder
- Atrial fibrillation
- Angina pectoris
- Arrhythmia
- Bradycardia
- Dyspepsia
- Myalgia
- Tachycardia
Look up ABIRATERONE in the interactive SynDRA portal →